Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Y Pak

Showing results (131-140 of 312) with videos related to

Pageof 32
Sort By:
Endocrinology|November 1, 1987
Administration of pharmacological amounts of 25(s),26-dihydroxyvitamin D3 reduces serum 1,25-dihydroxyvitamin D3 levels in ratsJ E Zerwekh, J A Harvey, C Y Pak
Journal of Endourology|December 23, 1999
Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasisM S Pearle, C G Roehrborn, C Y Pak
The Journal of Lithotripsy & Stone Disease|April 1, 1990
Similarity of urinary risk factors among stone-forming patients in five regions of the United StatesJ A Harvey, K D Hill, C Y Pak
The American Journal of Medicine|January 1, 1995
Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocolF L Levy, B Adams-Huet, C Y Pak
The Urologic Clinics of North America|February 1, 1997
Medical therapy, calcium oxalate urolithiasisL A Ruml, M S Pearle, C Y Pak
Urology|October 24, 1997
Ethnic and geographic diversity of stone diseaseC Y Pak, M I Resnick, G M Preminger
Kidney International|September 1, 1983
Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming saltsK Sakhaee, M Nicar, K Hill, et al.
Journal of Clinical Pharmacology|January 1, 1984
Augmentation of renal citrate excretion by oral potassium citrate administration: time course, dose frequency schedule, and dose-response relationshipC Y Pak, C Skurla, L Brinkley, et al.
The Journal of Laboratory and Clinical Medicine|April 1, 1977
Estimation of the state of saturation of brushite and calcium oxalate in urine: a comparison of three methodsC Y Pak, Y Hayashi, B Finlayson, et al.
Human Mutation|March 29, 2000
Identification of two novel mutations [P122S (364C>T) and 1601delAC] in the SLC3A1 gene in type I cystinuricsW L Gitomer, B Y Reed, C Y Pak
Pageof 32

Showing results (131-140 of 312) with videos related to

Sort By:
Pageof 32
Endocrinology|November 1, 1987
Administration of pharmacological amounts of 25(s),26-dihydroxyvitamin D3 reduces serum 1,25-dihydroxyvitamin D3 levels in ratsJ E Zerwekh, J A Harvey, C Y Pak
Journal of Endourology|December 23, 1999
Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasisM S Pearle, C G Roehrborn, C Y Pak
The Journal of Lithotripsy & Stone Disease|April 1, 1990
Similarity of urinary risk factors among stone-forming patients in five regions of the United StatesJ A Harvey, K D Hill, C Y Pak
The American Journal of Medicine|January 1, 1995
Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocolF L Levy, B Adams-Huet, C Y Pak
The Urologic Clinics of North America|February 1, 1997
Medical therapy, calcium oxalate urolithiasisL A Ruml, M S Pearle, C Y Pak
Urology|October 24, 1997
Ethnic and geographic diversity of stone diseaseC Y Pak, M I Resnick, G M Preminger
Kidney International|September 1, 1983
Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming saltsK Sakhaee, M Nicar, K Hill, et al.
Journal of Clinical Pharmacology|January 1, 1984
Augmentation of renal citrate excretion by oral potassium citrate administration: time course, dose frequency schedule, and dose-response relationshipC Y Pak, C Skurla, L Brinkley, et al.
The Journal of Laboratory and Clinical Medicine|April 1, 1977
Estimation of the state of saturation of brushite and calcium oxalate in urine: a comparison of three methodsC Y Pak, Y Hayashi, B Finlayson, et al.
Human Mutation|March 29, 2000
Identification of two novel mutations [P122S (364C>T) and 1601delAC] in the SLC3A1 gene in type I cystinuricsW L Gitomer, B Y Reed, C Y Pak
Pageof 32